It is no question how much COVID-19 has reminded us just how important life sciences and drug creation can be. Moreover, the companies developing these life changing drugs need the support and technology to perform impactfully. 

Our client, Sensyne Health, is always innovating in the world of healthcare IT and medical research. Known as the ethical AI company, Sensyne gathers, curates and analyses clinical data, primarily de-identified patient records, to develop insights for drug creators and health systems in order to improve patient care and accelerate medical research.

Recently, Sensyne launched its new patient data analytics platform, SENSIGHT, which democratizes key aspects of life sciences research by providing access to a massive data set across a range of different disease areas. One of our first approaches to this launch included identifying the parts of SENSIGHT that would be most interesting to Sensyne’s target audiences. We wanted to share the ways the database will elevate access to de-identified data insights for clinicians and drugmakers, helping them to make drugs to benefit people like you and me. Below are the components of SENSIGHT we felt would be attractive for Sensyne’s key stakeholders.

Privacy

• As the ethical AI company, Sensyne understands and has pioneered the necessity of patient data privacy.
• That is why SENSIGHT is built on a rapidly growing de-identified patient data set created from research partnerships.

Growing Dataset

• The platform has launched with access to a 2M de-identified data set and is expected to grow to 10M by the end of the year.
• It is not just quantity that is increasing, but the types of disease areas that will be added throughout the year within the platform.

Collaboration

• Subscribers can communicate with each other using the service, which provides the space for a virtual scientific research network.
• This network of healthcare professionals will create a community and make way for further development and innovation.

By including these messages in our pitch, we displayed how SENSIGHT can provide the insights to support the development for life-changing drug discovery, and the media seemed to agree. We were able to secure a stream of coverage in key publications like FierceBiotech and PharmaVoice.

If you or your company are interested in elevating your brand through PR, you can reach out to Scott Collins at scollins@ariamarketing.com and we can talk about how our team can help you. You can also follow us on Twitter and LinkedIn to stay up to date on everything Aria.

It’s that time of year again! You guessed it. It’s HIMSS time. HIMSS, otherwise known as the Healthcare Information Management Systems Society, is hosting its annual global health conference and exhibition in Orlando next month. The event brings together tens of thousands of health IT professionals, clinicians, executives, and market suppliers around the world – and consequently, healthcare media, who flock to learn more about the latest industry trends and innovations. As such, it’s always a highly prioritized event for the majority of our clients. HIMSS, or as we (and the rest of the industry) fondly refer to it, “HIMSSanity,” is considered one of the most prominent events across the entire healthcare industry.

For 25 years, Michael Dowding has pursued the twin passions of writing and education as a freelance writer and professor at Boston University’s College of Communication. In addition to thousands of content-writing projects and several ghostwritten books, his BU classes on media writing and popular workshops for the PR Club of New England have helped him devise and refine the writing principles that he loves to share. Following his guest lecture for Aria Marketing, we caught up with Michael to get his latest take on the current state of professional media writing.

While some companies may slow down during the summer months, the Aria team turned up the heat and kept our activities flowing - and the results show. We secured noteworthy coverage for our clients and provided them with opportunities to share their expertise in several prominent publications in Q3.